Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)

American Journal of Medical Genetics, Part A

Volumn 155, Issue 9, 2011, Pages 2257-2262

  Marucha, Jolanta ^a   Tylki Szymańska, Anna ^a   Jakóbkiewicz Banecka, Joanna ^b   Piotrowska, Ewa ^b   Kloska, Anna ^b   Czartoryska, Barbara ^c   Wegrzyn, Grzegorz ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Gene expression targeted isoflavone therapy; Genistein; Hunter disease; Joint motion; Mucopolysaccharidoses; Substrate reduction therapy

Indexed keywords

GENISTIN; ISOFLAVONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUNTER SYNDROME; JOINT FUNCTION; MALE; MOLECULARLY TARGETED THERAPY; MOTOR PERFORMANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANGE OF MOTION; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADULT; CHILD; CONNECTIVE TISSUE; GENE EXPRESSION; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; ISOFLAVONES; MALE; MOLECULAR TARGETED THERAPY; MUCOPOLYSACCHARIDOSIS II; RANGE OF MOTION, ARTICULAR;

ANIMALIA;

EID: 81155160850     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.34146     Document Type: Article

References (28)

1. Alcalde-Martín C, Muro-Tudelilla JM, Cancho-Candela R, Gutiérrez-Solana LG, Pintos-Morell G, Martí-Herrero M, Munguira-Aguado P, Galán-Gómez E. 2010. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS). Eur J Med Genet 53: 371-377.
2. Burrow TA, Leslie ND. 2008. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2: 311-320.
3. Carrino DA, Sorrell JM, Caplan AI. 2000. Age-related changes in the proteoglycans of human skin. Arch Biochem Biophys 373: 91-101.
4. Cox-Brinkman J, Smeulders MJ, Hollak CE, Wijburg FA. 2007. Restricted upper extremity range of motion in mucopolysaccharidosis type I: No response to one year of enzyme replacement therapy. J Inherit Metab Dis 30: 47-50.
5. Dziedzic D, Wegrzyn G, Jakóbkiewicz-Banecka J. 2010. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: A potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet 18: 200-205.
6. Friso A, Tomanin R, Salvalaio M, Scarpa M. 2010. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 159: 1082-1091.
7. Gerhardt JJ, Rondinelli RD. 2001. Goniometric techniques for range-of-motion assessment. Phys Med Rehabil Clin N Am 12: 507-527.
8. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G. 2007. Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 48: 383-388.
9. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G. 2009. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16: 26.
10. Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S. 2010. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet 18: 194-199.
11. Lim-Melia ER, Kronn DF. 2009. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann 38: 448-455.
12. Malinowska M, Jakobkiewicz-Banecka J, Kloska A, Tylki-Szymanska A, Czartoryska B, Piotrowska E, Wegrzyn A, Wegrzyn G. 2008. Abnormalities in the hair morphology of patients with some but not all types of mucopolysaccharidoses. Eur J Pediatr 167: 203-209.
13. Malinowska M, Wilkinson FL, Bennett W, Langford-Smith KJ, O'Leary HA, Jakobkiewicz-Banecka J, Wynn R, Wraith JE, Wegrzyn G, Bigger BW. 2009. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 98: 235-242.
14. Murata K, Horiuchi Y. 1978. Age-dependent distribution of acidic glycosaminoglycans in human kidney tissue. Nephron 20: 111-118.
15. Neufeld EF, Muenzer J. 2001. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, 8th edition. New York: McGraw-Hill Co. pp 3421-3452.
16. Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, Eto Y, Orii T. 2010. Japan Elaprase Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 99: 18-25.
17. Olczyk K. 1993. Age-related changes in glycosaminoglycans of human intervertebral discs. Folia Histochem Cytobiol 31: 215-220.
18. Pennock CA. 1976. A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of mucopolysaccharidoses. J Clin Pathol 29: 111-123.
19. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G. 2006. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14: 846-852.
20. Piotrowska E, Jakobkiewicz-Banecka J, Tylki-Szymanska A, Liberek A, Maryniak A, Malinowska M, Czartoryska B, Puk E, Kloska A, Liberek T, Baranska S, Wegrzyn A, Wegrzyn G. 2008. Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp
21. Piotrowska E, Jakóbkiewicz-Banecka J, Maryniak A, Tylki-Szymańska A, Puk E, Liberek A, Wegrzyn A, Czartoryska B, Slomińska-Wojewódzka M, Wegrzyn G. 2011. Two years follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: Assessment of effects on cognitive functions and general status of patients. Med Sci Monit 17: CR196-202.
22. Rohrbach M, Clarke JT. 2007. Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy. Drugs 67: 2697-2716.
23. Tomatsu S, Gutierrez MA, Ishimaru T, Peña OM, Montaño AM, Maeda H, Velez-Castrillon S, Nishioka T, Fachel AA, Cooper A, Thornley M, Wraith E, Barrera LA, Laybauer LS, Giugliani R, Schwartz IV, Frenking GS, Beck M, Kircher SG, Paschke E, Yamaguchi S, Ullrich K, Isogai K, Suzuki Y, Orii T, Noguchi A. 2005. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 28: 743-757.
24. Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B. 2010a. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 33: 151-157.
25. Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B. 2010b. Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab 99: 10-17.
26. Voznyi YV, Keulemans JL, van Diggelen OP. 2001. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 24: 675-680.
27. Wegrzyn G, Jakobkiewicz-Banecka J, Gabig-Ciminska M, Piotrowska E, Narajczyk M, Kloska A, Malinowska M, Dziedzic D, Golebiewska I, Moskot M, Wegrzyn A. 2010. Genistein: A natural isoflavone with a potential for treatment of genetic diseases. Biochem Soc Trans 38: 695-701.
28. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT, Zeman J. 2008. Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167: 267-277.